21 studies found for:    " November 09, 2011":" December 09, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" November 09, 2011":" December 09, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df;   Drug: ritonavir-boosted protease inhibitor plus Truvada
2 Active, not recruiting Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations
Conditions: Tobacco Cessation;   HIV;   AIDS
Interventions: Behavioral: Treatment as usual;   Behavioral: AIR (Aspirations, Inspiration, Respiration)
3 Completed A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART
Condition: HIV Infection
Interventions: Drug: Vaccination;   Drug: Placebo
4 Recruiting Use of Incentives to Retain Drug Users in HIV Therapy
Condition: HIV Infection
Intervention: Other: monetary reinforcer
5 Terminated Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors
Condition: HIV Infection
Intervention:
6 Active, not recruiting Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors
Condition: HIV-1 Infection
Interventions: Drug: Isentress® (Raltegravir, 400 mg every 12 hours);   Drug: Isentress® (Raltegravir, 400 every 12 hours)
7 Completed Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men
Conditions: Human Immunodeficiency Virus Infection;   Sexually Transmitted Diseases
Interventions: Behavioral: Men Making a Difference HIV/STD Risk Reduction Intervention;   Behavioral: Health Promotion Control
8 Recruiting Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression
Condition: HIV Infection
Intervention: Drug: antiretroviral treatment
9 Active, not recruiting Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
Conditions: HIV Infections;   Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN);   Drug: Ribavirin (RBV);   Drug: Boceprevir (BOC)
10 Not yet recruiting Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women
Condition: HIV Infections
Interventions: Drug: 1% tenofovir gel;   Drug: Placebo gel
11 Active, not recruiting Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C);   Biological: rAd5 env A;   Biological: rAd5 env B;   Biological: rAd5 env C;   Biological: rAd5 gag-pol;   Biological: Placebo Vaccine
12 Active, not recruiting Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Condition: HIV-1 Infection
Interventions: Drug: BMS-986001;   Drug: Placebo matching with BMS-986001;   Drug: Efavirenz;   Drug: Lamivudine;   Drug: Tenofovir
13 Recruiting Lipopeptide Immunisation With GTU-multiHIV Trial
Condition: HIV-1 Infection
Interventions: Biological: Placebos of GTU-multiHIV B and LIPO-5 vaccines;   Biological: GTU-multHIV B vaccine and LIPO-5 vaccine
14 Recruiting WHC+ (Women's Health CoOp PLUS)
Conditions: HIV;   Sexual Risk;   Sexually Transmitted Diseases;   Substance Abuse;   Violence;   Victimization
Interventions: Behavioral: Test, Treat, Retain(TTR) + Women's Health CoOp (WHC);   Biological: Test, Treat, Retain(TTR) only
15 Active, not recruiting Early HIV Therapy in Patients With High CD4 Cell Counts
Condition: HIV
Interventions: Drug: Standard ART;   Drug: Study-Provided ART
16 Completed Antiretroviral Drug Interaction Study in Volunteers With HIV
Conditions: HIV;   PCP;   Toxoplasmosis
Interventions: Drug: Atovaquone 750 mg twice daily;   Drug: Atovaquone 1500 mg twice daily
17 Recruiting Reducing High Risk Behavior in Drug Court
Conditions: Substance Abuse;   HIV
Interventions: Behavioral: Computer-facilitated HIV intervention;   Behavioral: Attention Control
18 Unknown  Men of African American Legacy Empowering Self
Condition: HIV
Interventions: Behavioral: Men of African American Legacy Empowering Self;   Behavioral: Standard HIV Education & Risk Reduction
19 Recruiting A Smoking Cessation Trial in HIV-infected Patients in South Africa
Conditions: Smoking Cessation;   HIV
Interventions: Drug: Nicotine;   Behavioral: Intensive Counseling
20 Active, not recruiting Preparedness Study - HPV Vaccine
Condition: Sexual Transmission of Infection
Interventions: Biological: Gardasil Vaccine;   Biological: Placebo Vaccine

Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results
Indicates status has not been verified in more than two years